“…Paeoniflorin, a terpenoid glycoside compound extracted from Paeonia lactiflora Pall, holds significant promise for treating neurological disorders, including stroke, Alzheimer's disease and PD due to its unique biological activities and pharmacological effects, which encompass antioxidative, anti‐inflammatory, autophagy regulation, enhancement of cholinergic nerve function, maintenance of ion channel homeostasis, suppression of neuronal apoptosis, and promotion of neuronal nutrition (Hong et al, 2022). In mouse models of PD induced by MPTP, rotenone or 6‐OHDA, both pretreatment and posttreatment with paeoniflorin could mitigate deficits in motor performance, α‐Syn accumulation and the loss of dopaminergic neurons through several mechanisms: (1) Inhibition of mitochondrial apoptosis by upregulating the Bcl‐2/BAD ratio and Bcl‐2/BAX ratio, downregulating cleaved caspase‐3 expression, and reducing caspase‐3/9 activities; (2) Attenuation of mitochondrial‐related oxidative stress by promoting Nrf2 nuclear translocation, leading to the activation of the Nrf2 pathway and subsequent induction of HO‐1 and SOD expression (Guo et al, 2021; Zhang et al, 2023; Zheng et al, 2017). In MPP + ‐treated PC12 cells, paeoniflorin also has been shown to inhibit α‐Syn aggregation, oxidative stress and apoptosis by modulating the autophagy‐lysosome and ubiquitin‐proteasome pathways (in part by inhibiting acid‐sensing ion channels), ultimately enhancing autophagic activity (Hong et al, 2022; Sun et al, 2011).…”